Peroxisome proliferator–activated receptors (PPARs) are nuclear cell transcription factors with isoform agonists that exhibit clinical benefit. The PPAR-γ agonists increase insulin sensitivity, explaining the antidiabetic action of the thiazolidinediones rosiglitazone and pioglitazone. PPAR-α agonists, including the fibrates, increase fatty acid oxidation, leading to a decrease in plasma triglycerides and a modest increase in high-density lipoprotein cholesterol. Muraglitazar is the first dual-PPAR agonist to be considered for general marketing both as monotherapy and combined therapy by the US Food and Drug Administration (FDA). Given the emerging epidemic of type 2 diabetes, it is easy to understand the enthusiasm for this new class of drugs. Tight glycemic control reduces diabetic microvascular complications, although both old1 and new2 studies have failed to convincingly show decreased macrovascular complications of stroke, cardiac disease, and peripheral vascular disease.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 12
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Can I Apply the Results of the Study to My Patient?
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.